Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Abstract The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type o...

Full description

Bibliographic Details
Main Authors: Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Molecular Cancer
Subjects:
Immunotherapy
Immune checkpoint
LAG-3
TIM-3
TIGIT
VISTA
Online Access:http://link.springer.com/article/10.1186/s12943-019-1091-2

Internet

http://link.springer.com/article/10.1186/s12943-019-1091-2

Similar Items